Freshly isolated rat kidney cells with functional megalin transport provide a reliable screening tool to predict kidney accumulation of radiolabeled therapeutic peptides.
Megalin-expressing cellsfreshly isolated from rat kidneys retained the key transport system driving renal peptide accumulation, enabling reliable in vitro screening
What the researchers found
Freshly isolated rat renal cells were validated as an effective screening tool for evaluating kidney uptake of radiolabeled peptides. The cells maintained functional megalin transport systems (a key driver of renal peptide accumulation), confirmed by colocalization experiments showing proximal tubular cells bearing megalin. The method was successfully tested with indium-111 and lutetium-177 labeled analogs of somatostatin and gastrin, demonstrating its applicability for comparative renal accumulation studies.
Why it matters
Kidney accumulation is one of the biggest obstacles to using radiolabeled peptides in nuclear medicine for cancer imaging and therapy. Having a reliable in vitro screening tool to predict and compare kidney uptake early in development could accelerate the design of safer peptide radiopharmaceuticals with reduced nephrotoxicity.
The numbers in context
Somatostatin and gastrin analogs tested · indium-111 and lutetium-177 radiolabels · megalin transport system confirmed · proximal tubular cell markers validated
How the study worked
Rat renal cells were isolated by collagenase digestion. Megalin expression was compared across cell models via Western blotting. Proximal tubular cells were confirmed by immunohistochemistry with specific markers and megalin colocalization. The system was validated by measuring uptake of compounds with known renal accumulation patterns, then tested with radiolabeled somatostatin and gastrin peptide analogs.
Who was studied
Freshly isolated rat kidney cells (in vitro methodology study)
What this study cannot tell us
Rat renal cells may not perfectly model human kidney peptide handling. Freshly isolated cells have a limited lifespan, which may affect reproducibility and throughput. The study validates the method but does not yet use it to compare or optimize novel peptide candidates. Translation to human renal cell models would strengthen the platform.
How to read the evidence
This is a methodological validation study demonstrating proof of concept for a new in vitro screening platform. It successfully tested known radiolabeled peptides but represents a tool development paper rather than a therapeutic efficacy study.
When this study was published
Published in 2023, this method arrives as peptide radionuclide therapies are rapidly expanding in oncology following the FDA approval of lutetium-177-DOTATATE (Lutathera) in 2018.
The bigger picture
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs like lutetium-177-DOTATATE is already approved for treating neuroendocrine tumors. Kidney toxicity remains the dose-limiting factor. Better preclinical tools to predict and reduce renal uptake could enable higher therapeutic doses, expand the range of treatable cancers, and support the development of next-generation radiolabeled peptides.
Questions still open
- Could this screening platform identify peptide modifications that reduce kidney uptake while maintaining tumor targeting?
- How well do the rat kidney cell results predict actual human renal accumulation of radiolabeled peptides?
- Can this method be adapted to screen kidney-protective co-treatments (like amino acid infusions) used during peptide radionuclide therapy?
Common questions
Why do radiolabeled peptide drugs accumulate in the kidneys?
What are somatostatin and gastrin analogs used for in nuclear medicine?
Read the original research
Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney.
Pharmaceuticals (Basel, Switzerland), 16(5)
Citation
Barta, Pavel; Nachtigal, Petr; Maixnerova, Jana; Zemankova, Lenka; Trejtnar, Frantisek. (2023). Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney.. Pharmaceuticals (Basel, Switzerland), 16(5). https://doi.org/10.3390/ph16050696